Invitation to presentation of Q-linea’s Interim Report Q1-2019 on May 3, 2019

Q-linea AB (publ) (Nasdaq Stockholm: QLINEA), to publish the company’s Interim Report for the period January – March 2019 on Friday, May 3, 2019 at 07:30 a.m. CET.

Q-linea invites to an audiocast with teleconference (in English) for investors, analysts and media on May 3, at 13:00 – 14:00 p.m CET.

Jonas Jarvius, CEO, and Anders Lundin, CFO, to present Q-linea and comment on the Interim Report Report for the period January – March 2019 followed by a Q&A-session.

  
To participate, please call any of the following phone numbers from:
Sweden: + 46 8 505 583 51
UK: + 44 333 300 9263
US: + 1 833 526 8380

Webcast: https://tv.streamfabriken.com/q-linea-q1-2019


     
For more information, please contact:

Anders Lundin, CFO, Q-linea AB 
anders.lundin@qlinea.com 
+46 (0)70-600 15 20

The information was submitted for publication at 10:00 CET on April 26, 2019.

About Q-linea

Q-linea is an innovative research, development and manufacturing company that primarily develops instruments and disposables for rapid and reliable infection diagnostics. Q-linea’s vision is to help save lives by ensuring antibiotics continue to be an effective treatment for future generations. Q-linea develops and delivers preferred solutions for healthcare providers, enabling them to accurately diagnose and treat infectious disease in the shortest possible time. The company’s lead product ASTar™ is a fully automated instrument for antibiotic susceptibility testing (AST), giving a susceptibility profile within six hours directly from a positive blood culture. For more information, please visit www.qlinea.com.

Tags:

About Us

Q-linea is an innovative infection diagnostics company that primarily develops instruments and disposables for rapid and reliable infection diagnostics. Our vision is to help save lives by ensuring antibiotics continue to be an effective treatment for future generations. Q-linea develops and delivers preferred solutions for healthcare providers, enabling them to accurately diagnose and treat infectious disease in the shortest possible time. The company’s lead product ASTar® is a fully automated instrument for antibiotic susceptibility testing (AST), giving a susceptibility profile within six hours directly from a positive blood culture. For more information, please visit www.qlinea.com.

Subscribe

Documents & Links